Episode Transcript
[00:00:03] In the early 20th century, the assumption was simple. Animal cells in culture could divide without limit as long as nutrients and culture conditions were maintained. This view came largely from the work of Alexis Correll, and it was known as the correl dogma. For nearly five decades it shaped thinking about proliferation, aging and tissue maintenance.
[00:00:24] Then, in 1961, Leonard Hayflick and Paul Moorhead showed that normal human fibroblasts on undergo only a finite number of divisions before entering an irreversible growth arrest.
[00:00:36] The cells were alive. They had simply stopped.
[00:00:44] This is base by base. Every episode is built with AI tools from a real open access paper curated by a human, and every claim is checked against the paper before we publish. You'll find this episode's fact check score on our website.
[00:00:58] Now back to the.
[00:01:05] That arrest is called cellular senescence. For a long time it looked like a cell culture curiosity or a simple sign of cellular aging. Today it is linked to tumor suppression, wound healing, embryonic development, chronic disease, and aging itself. And it has become a drug target.
[00:01:24] How can a single process do all of that? Why would evolution conserve something capable of driving disease? And why have some of the first drugs against it failed in human trials? A review article traces how the answers changed over more than six decades.
[00:01:44] Today we celebrate the work of Mirte Klaver, Lotte, Sophie Stineken, Naomi Veiningen, Abdullah Altulia, and Marco Di Maria from the European Research Institute for the Biology of Aging, the University of Groningen, and the University Medical Center Groningen in the Netherlands, who have advanced our understanding of cellular senescence.
[00:02:06] This base by base episode is based on their Open Access review article Cellular Six Decades of Discovery and Reinvention, published in the EMBO Journal in October 2026.
[00:02:19] Because this is a review, the findings we discuss come from many studies which the author.
[00:02:30] A major mechanistic breakthrough came nearly three decades after Hayflick, Harley and colleagues proposed that progressive telomere shortening underlies replicative senescence. Telomeres are repetitive DNA sequences that protect chromosome ends. Conventional DNA replication cannot fully copy those ends, so they shorten with cell division. Once a critical threshold is reached, dysfunctional telomeres trigger a persistent DNA damage response, which enforces a stable cell cycle arrest.
[00:03:00] Later work showed that telomere erosion is a causal determinant of cellular lifespan. A descriptive phenomenon had become a mechanism that could be tested.
[00:03:11] The next question was whether senescence cells exist in living tissue that required markers. In 1995, Dimry and colleagues identified senescence associated beta galactosidase detectable at a Ph of 6 it became the most widely used method and gave some of the first evidence that senescent cells accumulate in vivo. But increased lysosomal activity is not unique to senescence.
[00:03:39] Researchers then defined two central pathways, P53 to P21 and P16 to RB. They also found DNA damage, foci and chromatin changes. The lesson, according to the authors, is that no no single marker defines senescence.
[00:03:58] Then the field changed direction. In 1997, Serrano and colleagues showed that oncogenic RAS signaling induces senescence in primary human and rodent cells. This was called oncogene induced senescence. Senescence no longer looked like a mere consequence of cellular aging. It looked like an active stress response program, a barrier to malignant transformation.
[00:04:21] There was also a species difference in rodent cells. Disrupting either P53 or P16 was enough to bypass senescence. Human cells required both pathways to be inactivated.
[00:04:32] Recent work suggests oncogene induced senescence is a spectrum of states, not one uniform endpoint.
[00:04:41] The triggers kept multiplying. Gamma irradiation induced a permanent arrest in the early 1990s and bleomycin, actinomycin D and doxorubicin produced senescence associated phenotypes too.
[00:04:55] Oxidative stress could cause proliferative arrest, and reactive oxygen species from dysfunctional mitochondria could induce senescence through DNA damage dependent and independent mechanisms.
[00:05:07] Many stimuli converged on a persistent DNA damage response, so senescence could be induced without telomere shortening.
[00:05:15] The authors call that realization one of the most important conceptual advances in the history of the field.
[00:05:21] Senescence had become a versatile response to cellular damage.
[00:05:29] For a long time, senescent cells were seen as arrested and inert. That changed through a major conceptual breakthrough. The first evidence came from the laboratory of Judy Campisi. Kratolica and colleagues showed that senescent fibroblasts stimulate the proliferation of pre neoplastic epithelial cells. While having little effect on normal epithelial cells, these cells were affecting their neighbors. Through a series of influential studies, the senescence associated secretory phenotype, or sasp, emerged as a defining feature. It is a collection of secreted cytokines, chemokines, growth factors and matrix remodeling enzymes. Senescent cells were actively communicating with their surroundings.
[00:06:18] The picture then grew more complicated. SASP expression proved dynamic, with most factors appearing several days after senescence induction. Unbiased profiling revealed bioactive lipids and extracellular vesicles carrying proteins and nucleic acids.
[00:06:35] And there is no single universal SASP secretory programs vary with cell type, tissue inducer, and signaling pathway.
[00:06:44] Some P53 to P21 programs promote immune surveillance others are dominated by pro inflammatory and pro tumorigenic factors. NF kappa B and CEBP beta were the first major regulators described. Other pathways followed. This diversity helps explain why senescent cells can have such different effects.
[00:07:08] For decades, though, the link to aging and disease remained largely correlative. Senescent cells appeared in aged tissues, but were they causing damage or just accumulating as a consequence of it? The field needed a way to remove them. The first widely used tool was the ink attack mouse, in which P16 positive cells can be selectively ablated through inducible apoptosis.
[00:07:32] Using this system, Baker and colleagues showed that senescent cell clearance delays age associated pathology in progeroid mice.
[00:07:40] Later studies reported improvements in health span and lifespan in naturally aged animals. These experiments gave some of the first direct evidence for a causal role, But the results were not universal. An independent P16 lineage tracing and ablation study reported that eliminating P16 expressing cell lineages can harm liver function. Reporter models can also disagree, as a recent debate over the P16 3 Mr. Model shows. Newer lineage specific approaches have found that senescent cells from different tissues can have distinct functions, so the effect of removing these cells depends on the population targeted and on the experimental context. That caution matters because a parallel series of studies was finding that senescent cells cells are sometimes useful consider repair in liver fibrosis. Krishinovsky and colleagues showed that activated hepatic stellate cells undergo senescence and that this limits excessive extracellular matrix deposition in skin. Senescent fibroblasts accumulate transiently during wound healing. Then came direct evidence from genetic ablation.
[00:08:55] Demaria and colleagues showed that eliminating senescent cells delays wound closure. Senescent fibroblasts promote myofibroblast differentiation through the secretion of pdgfaa, which accelerates healing. Senescent cells were not merely present during repair they actively contributed to it.
[00:09:14] Studies then extended these findings to regeneration in other organisms. Although the evidence in models such as planarians remains limited, an even more unexpected result arrived in 2013.
[00:09:29] Two independent groups reported senescent cells during embryonic development in transient structures such as the mesonephric tubules and the apical ectodermal ridge. Developmental senescence depends largely on P21 and occurs independently of both P16 and P53.
[00:09:48] It was later found in birds, amphibians, and fish, so senescence can be initiated through distinct mechanisms and generate a similar phenotype. The authors suggest it may not have evolved solely as a tumor suppressive mechanism or as a consequence of aging. It may be an ancient tissue remodeling program later adapted for other functions.
[00:10:12] While those roles were emerging, the link to aging kept growing. Starting in the 1990s and early 2000s, studies reported more senescence associated markers in aged tissues, including skin, adipose tissue, liver, kidney, and lung. Telomere dysfunction, genomic instability, mitochondrial dysfunction, and chronic inflammation can all induce or reinforce senescence programs. That central position helped bring cellular senescence into the hallmarks of aging framework, where it was recognized as a fundamental process contributing to organismal aging.
[00:10:51] That helps with a paradox. How does a useful program become a driver of disease? The authors point to persistence. Senescence appears beneficial when it is induced transiently and cleared efficiently. When senescent cells persist exist because of continuous damage, repeated stress, or inefficient immune clearance, they accumulate and harm tissue homeostasis.
[00:11:14] Aging can then be viewed, at least in part, as a progressive imbalance between the generation and removal of senescent cells.
[00:11:22] The SASP links this to disease. Its factors promote vascular inflammation, plaque progression, and insulin resistance and contribute to fibrosis, osteoporosis, and tumor progression. Progression.
[00:11:37] There is a striking cancer paradox here. Senescence suppresses malignant transformation in the cell that arrests. Yet senescent cells can promote tumor progression at the tissue level, Factors such as IL6, IL8, and VEGF have been reported to promote tumor growth, angiogenesis, invasion, and metastasis.
[00:11:58] So why do senescent cells persist at all?
[00:12:01] The answer lies at least partly with the immune system. In 2007, Xu and colleagues showed that restoring p53 in liver tumors induces senescence and triggers tumor regression through an immune dependent mechanism. Senescent cells were being actively removed.
[00:12:20] Later work added more detail.
[00:12:22] CD4T cells contribute to clearing senescent hepatocytes.
[00:12:26] NK cells can directly eliminate senescent cells. The SASP helps recruit these immune cells.
[00:12:33] Clearance also depended on the receptor NKG2D.
[00:12:37] But senescent cells can resist.
[00:12:40] In 2019, Pereira and colleagues showed that they upregulate HLAE, which interacts with the inhibitory receptor NKG2A and suppresses cytotoxic activity.
[00:12:51] Aging adds a fertile further problem. Immunosenescence, reduced NK cell cytotoxicity and impaired macrophage function may lower clearance, and persistent SASP signaling can worsen immune dysfunction.
[00:13:08] If senescent cells can cause harm, can they be treated? Two strategies emerged. Senolytics aim to eliminate senescent cells. Senescent cells are remarkably resistant to apoptosis and depend on a network of pro survival pathways. In 2015, Zhu and colleagues identified the first senolytic combination, dasitinib plus quercetin. It showed efficacy in multiple preclinical models. Navitoclax, a BCL2 family inhibitor, followed, but dose limiting hematological toxicities exposed a central problem.
[00:13:43] Many survival pathways used by senescent cells are shared with normal cells.
[00:13:48] Later designs targeted other vulnerabilities, including elevated lysosomal beta galactosidase for selective prodrug activation.
[00:13:59] The second strategy is since senescent cells contribute to repair, regeneration and development, removing all of them raised concern.
[00:14:09] Xenomorphics instead aimed to suppress detrimental activities, particularly the SASP, without necessarily killing the cell. Inhibiting P38 MAP kinase reduced the SASP, glucocorticoids attenuated it, rapamycin suppressed multiple pro inflammatory factors, and ruxolitinib reduced inflammatory SASP components. In experimental models, there is a tradeoff because the these interventions do not necessarily reduce the number of senescent cells. Those cells could resume their harmful activity if treatment stops. The authors note that this possibility stays open.
[00:14:47] Human studies came next. The first published clinical senolytic study was in 2019 in idiopathic pulmonary fibrosis. Intermittent dasatinib plus quercetin was feasible and associated with improvements in fibrous physical function.
[00:15:03] A study in diabetic kidney disease then reported reduced senescence associated markers in adipose tissue and skin biopsies.
[00:15:10] A phase one study in mild Alzheimer's disease found the treatment well tolerated with measurable central nervous system exposure. But conclusions from a randomized pilot study remained limited by sample size and design.
[00:15:24] Fisetin has entered early evaluation and evidence for clinical benefit remains remains preliminary.
[00:15:32] Then came the setbacks. Ubx0101 a senolytic for osteoarthritis showed encouraging efficacy in preclinical models, yet phase two studies failed to demonstrate significant clinical benefit and the program was discontinued.
[00:15:49] Ubx1325a bcl xl targeting senolytic for diabetic macular edema showed favorable safety and early signs of biological activity, but failed to meet its primary endpoint. In phase 2b.
[00:16:03] The authors draw a clear Demonstrating senolytic activity in experimental systems does not necessarily translate into measurable clinical efficacy in humans.
[00:16:16] Why is it so hard? The authors name a major bottleneck the the lack of validated biomarkers that can show target engagement in vivo markers such as P16 P21 beta galactosidase and circulating SASP factors are useful, but they lack sufficient specificity and validation as definitive measures of senescent cell burden.
[00:16:40] So a trial can modulate an aging associated pathway without confirming a direct effect on senescent cells.
[00:16:48] Several xenomorphic studies did not directly assess that burden at all.
[00:16:53] Better measurement alone is unlikely to be enough, they add. It must progress alongside more potent and selective xenotherapeutics.
[00:17:04] The field is now moving toward precision single cell transcriptomics, spatial profiling and genetic models have revealed extensive heterogeneity among senescent cells cells across tissues, stimuli and biological contexts that challenges the idea that one intervention will work across all senescence associated conditions.
[00:17:25] Emerging approaches include targeted drug delivery, CAR T cells and antibody mediated targeting. The aim is to preserve beneficial senescent populations while targeting those that drive pathology.
[00:17:37] We should note what this article is it is a narrative review, not a new experiment, and much of the causal evidence described here comes from mouse models.
[00:17:51] So here is where this leaves us. Senescence began as a limit on cell division in culture. It became a tumor suppressive stress response, then a tissue remodeling program acting through the sasp, then a contributor to aging and disease, and finally a therapeutic target.
[00:18:09] The authors conclude that senescence is neither inherently beneficial nor inherently detrimental. Its consequences are determined by context. Senescent cells can promote repair and tumor suppression. They can also drive chronic inflammation, fibrosis and functional decline.
[00:18:28] The authors expect the next phase to depend less on whether whether senescence is good or bad and more on which senescent cells in which tissues, at which stage of life or disease, and through which mechanisms. That is a demanding set of questions, and it will need robust biomarkers, standardized measurement and better patient stratification more than six decades after those cells stopped dividing in culture. What does this mean for the future of healthy aging if the goal is not simply to eliminate senescence cells cells but to manipulate senescence with precision.
[00:19:05] This episode was based on an Open Access article under the CC BY 4.0 license. You can find a direct link to the paper and the license in our episode description if you enjoyed this, follow or subscribe in your podcast app and leave a five star rating. If you'd like to support our work, use the donation link in the description. Thanks for listening and join us next time as we explore more science base by base.
